Skip to main content
Signal8

CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment

$CEROPress releaseJun 15, 2026, 8:15 AM ET

CERo Therapeutics reported a clinical update from its Phase 1 CERTAIN-T trial for CER-1236, noting that six patients have now been treated with no dose-limiting toxicities observed. Patient five, who had refractory acute myeloid leukemia, saw bone marrow blast counts drop from baseline to 7% by Day 42, enabling an allogeneic stem cell transplant on Day 71.

Key figures

Drug Name
CER-1236
Phase Of Trial
Phase 1
Dose patient 5
4 million cells/kg
Transplant day
71
Next cohort dose
1 billion cells/patient
Patients treated
6
Blast count day 14
14%
Blast count day 28
14%
Blast count day 42
7%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.